The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
Yogesh M BramhechaJacques Lapointe

Abstract

Prostate cancer is a clinically heterogeneous disease and accurately risk-stratifying patients is a key clinical challenge. We hypothesized that the concurrent identification of the DNA copy number alterations 10q23.3 (PTEN) deletion and 16p13.3 (PDPK1) gain, related to the PI3K/AKT survival pathway, would improve prognostication. We assessed PTEN deletion status using fluorescence in situ hybridization (FISH) and evaluated its clinical significance in combination with the 16p13.3 gain in a set of 332 primary radical prostatectomy cases on a tissue microarray with clinical follow-up. The PTEN deletion was detected in 34% (97/287) of the evaluable tumors and was significantly associated with high Gleason grade group (P < 0.0001) and advanced pathological tumor stage (pT-stage, P < 0.001). The PTEN deletion emerged as a significant predictor of biochemical recurrence independent of the standard clinicopathologic parameters (hazard ratio: 3.00, 95% confidence interval: 1.81-4.98; P < 0.0001) and further stratified patients with low and intermediate risk of biochemical recurrence [Gleason grade group 1-2 (≤3 + 4), Gleason grade group 2 (3 + 4), pT2, prostate-specific antigen ≤ 10, low and intermediate CAPRA-S score; log-rank P ≤ 0....Continue Reading

References

Aug 19, 1997·Proceedings of the National Academy of Sciences of the United States of America·M P MyersN K Tonks
Jun 6, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y E WhangC L Sawyers
Nov 9, 2000·Seminars in Hematology·A Gozzetti, M M Le Beau
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·B Kwabi-AddoM Ittmann
Sep 19, 2007·Cancer Research·Jacques LapointeJonathan R Pollack
May 2, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Bo HanRajal B Shah
Sep 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tamara L LotanAngelo M De Marzo
Feb 13, 2013·Translational Oncology·Khalil A ChoucairJacques Lapointe
Apr 27, 2013·Current Opinion in Urology·Sanoj Punnen, Matthew R Cooperberg
May 23, 2013·British Journal of Cancer·J CuzickUNKNOWN Transatlantic Prostate Group
May 21, 2014·Nature Reviews. Clinical Oncology·Albert J ChangHoward I Scher
Jul 16, 2014·Proceedings of the National Academy of Sciences of the United States of America·Haley HieronymusCharles L Sawyers
Aug 15, 2014·International Journal of Oncology·Paul Toren, Amina Zoubeidi
Dec 17, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurence KlotzAndrew Loblaw
May 27, 2015·International Journal of Cancer. Journal International Du Cancer·Martina KluthThorsten Schlomm
Nov 7, 2015·Cell·UNKNOWN Cancer Genome Atlas Research Network
Jan 12, 2016·The Journal of Molecular Diagnostics : JMD·Xiaoyu QuMin Fang
Jan 28, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maximilian LennartzThorsten Schlomm
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Oct 11, 2017·Molecular Cancer Research : MCR·Yogesh M BramhechaJacques Lapointe
May 17, 2018·Nature Reviews. Urology·Géraldine PignotDelphine Borchiellini

❮ Previous
Next ❯

Citations

Jul 31, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·R LiuT Li

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
biopsies
dissection

Software Mentioned

WinStat
Pro Plus
R
Image
SPSS

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.